Tags

Type your tag names separated by a space and hit enter

Booster dose after 10 years is recommended following 17DD-YF primary vaccination.
Hum Vaccin Immunother. 2016; 12(2):491-502.HV

Abstract

A single vaccination of Yellow Fever vaccines is believed to confer life-long protection. In this study, results of vaccinees who received a single dose of 17DD-YF immunization followed over 10 y challenge this premise. YF-neutralizing antibodies, subsets of memory T and B cells as well as cytokine-producing lymphocytes were evaluated in groups of adults before (NVday0) and after (PVday30-45, PVyear1-4, PVyear5-9, PVyear10-11, PVyear12-13) 17DD-YF primary vaccination. YF-neutralizing antibodies decrease significantly from PVyear1-4 to PVyear12-13 as compared to PVday30-45, and the seropositivity rates (PRNT≥2.9Log10mIU/mL) become critical (lower than 90%) beyond PVyear5-9. YF-specific memory phenotypes (effector T-cells and classical B-cells) significantly increase at PVday30-45 as compared to naïve baseline. Moreover, these phenotypes tend to decrease at PVyear10-11 as compared to PVday30-45. Decreasing levels of TNF-α(+) and IFN-γ(+) produced by CD4(+) and CD8(+) T-cells along with increasing levels of IL-10(+)CD4(+)T-cells were characteristic of anti-YF response over time. Systems biology profiling represented by hierarchic networks revealed that while the naïve baseline is characterized by independent micro-nets, primary vaccinees displayed an imbricate network with essential role of central and effector CD8(+) memory T-cell responses. Any putative limitations of this cross-sectional study will certainly be answered by the ongoing longitudinal population-based investigation. Overall, our data support the current Brazilian national immunization policy guidelines that recommend one booster dose 10 y after primary 17DD-YF vaccination.

Authors+Show Affiliations

a Centro de Pesquisas René Rachou; FIOCRUZ ; Minas Gerais , Brazil.a Centro de Pesquisas René Rachou; FIOCRUZ ; Minas Gerais , Brazil.a Centro de Pesquisas René Rachou; FIOCRUZ ; Minas Gerais , Brazil.a Centro de Pesquisas René Rachou; FIOCRUZ ; Minas Gerais , Brazil.a Centro de Pesquisas René Rachou; FIOCRUZ ; Minas Gerais , Brazil.a Centro de Pesquisas René Rachou; FIOCRUZ ; Minas Gerais , Brazil.a Centro de Pesquisas René Rachou; FIOCRUZ ; Minas Gerais , Brazil.a Centro de Pesquisas René Rachou; FIOCRUZ ; Minas Gerais , Brazil.a Centro de Pesquisas René Rachou; FIOCRUZ ; Minas Gerais , Brazil.a Centro de Pesquisas René Rachou; FIOCRUZ ; Minas Gerais , Brazil.a Centro de Pesquisas René Rachou; FIOCRUZ ; Minas Gerais , Brazil.a Centro de Pesquisas René Rachou; FIOCRUZ ; Minas Gerais , Brazil.a Centro de Pesquisas René Rachou; FIOCRUZ ; Minas Gerais , Brazil.a Centro de Pesquisas René Rachou; FIOCRUZ ; Minas Gerais , Brazil.a Centro de Pesquisas René Rachou; FIOCRUZ ; Minas Gerais , Brazil.a Centro de Pesquisas René Rachou; FIOCRUZ ; Minas Gerais , Brazil.b Instituto de Tecnologia em Imunobiológicos Bio-Manguinhos-FIOCRUZ ; Rio de Janeiro , Brazil.b Instituto de Tecnologia em Imunobiológicos Bio-Manguinhos-FIOCRUZ ; Rio de Janeiro , Brazil.c Secretaria de Estado de Saúde; Governo do Estado de Minas Gerais; Belo Horizonte ; Minas Gerais , Brazil.b Instituto de Tecnologia em Imunobiológicos Bio-Manguinhos-FIOCRUZ ; Rio de Janeiro , Brazil.b Instituto de Tecnologia em Imunobiológicos Bio-Manguinhos-FIOCRUZ ; Rio de Janeiro , Brazil.b Instituto de Tecnologia em Imunobiológicos Bio-Manguinhos-FIOCRUZ ; Rio de Janeiro , Brazil.d Universidade Federal de Alfenas ; Alfenas , Minas Gerais , Brazil.e Instituto de Biologia do Exército ; Rio de Janeiro , Brazil.e Instituto de Biologia do Exército ; Rio de Janeiro , Brazil.e Instituto de Biologia do Exército ; Rio de Janeiro , Brazil.e Instituto de Biologia do Exército ; Rio de Janeiro , Brazil.e Instituto de Biologia do Exército ; Rio de Janeiro , Brazil.e Instituto de Biologia do Exército ; Rio de Janeiro , Brazil.f Assessoria Clínica de Bio-Manguinhos; FIOCRUZ ; Rio de Janeiro , Brazil.b Instituto de Tecnologia em Imunobiológicos Bio-Manguinhos-FIOCRUZ ; Rio de Janeiro , Brazil.b Instituto de Tecnologia em Imunobiológicos Bio-Manguinhos-FIOCRUZ ; Rio de Janeiro , Brazil.f Assessoria Clínica de Bio-Manguinhos; FIOCRUZ ; Rio de Janeiro , Brazil.g Secretaria de Vigilância em Saúde ; Ministério da Saúde , Brazil.g Secretaria de Vigilância em Saúde ; Ministério da Saúde , Brazil.h Universidade de Brasília ; Distrito Federal , Brazil.i Instituto Evandro Chagas-IEC ; Ananindeua , Pará , Brazil.j Center for Biologics Evaluation and Research-CBER; US Food and Drug Administration (FDA) ; Silver Spring , MD , USA.k Diretoria Regional de Brasília-Direb; FIOCRUZ ; Brasília , Brazil.l Escola Nacional de Saúde Pública; FIOCRUZ ; Rio de Janeiro , Brazil.a Centro de Pesquisas René Rachou; FIOCRUZ ; Minas Gerais , Brazil.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

26360663

Citation

Campi-Azevedo, Ana Carolina, et al. "Booster Dose After 10 Years Is Recommended Following 17DD-YF Primary Vaccination." Human Vaccines & Immunotherapeutics, vol. 12, no. 2, 2016, pp. 491-502.
Campi-Azevedo AC, Costa-Pereira C, Antonelli LR, et al. Booster dose after 10 years is recommended following 17DD-YF primary vaccination. Hum Vaccin Immunother. 2016;12(2):491-502.
Campi-Azevedo, A. C., Costa-Pereira, C., Antonelli, L. R., Fonseca, C. T., Teixeira-Carvalho, A., Villela-Rezende, G., Santos, R. A., Batista, M. A., Campos, F. M., Pacheco-Porto, L., Melo Júnior, O. A., Hossell, D. M., Coelho-dos-Reis, J. G., Peruhype-Magalhães, V., Costa-Silva, M. F., de Oliveira, J. G., Farias, R. H., Noronha, T. G., Lemos, J. A., ... Martins-Filho, O. A. (2016). Booster dose after 10 years is recommended following 17DD-YF primary vaccination. Human Vaccines & Immunotherapeutics, 12(2), 491-502. https://doi.org/10.1080/21645515.2015.1082693
Campi-Azevedo AC, et al. Booster Dose After 10 Years Is Recommended Following 17DD-YF Primary Vaccination. Hum Vaccin Immunother. 2016;12(2):491-502. PubMed PMID: 26360663.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Booster dose after 10 years is recommended following 17DD-YF primary vaccination. AU - Campi-Azevedo,Ana Carolina, AU - Costa-Pereira,Christiane, AU - Antonelli,Lis R, AU - Fonseca,Cristina T, AU - Teixeira-Carvalho,Andréa, AU - Villela-Rezende,Gabriela, AU - Santos,Raiany A, AU - Batista,Maurício A, AU - Campos,Fernanda M, AU - Pacheco-Porto,Luiza, AU - Melo Júnior,Otoni A, AU - Hossell,Débora M S H, AU - Coelho-dos-Reis,Jordana G, AU - Peruhype-Magalhães,Vanessa, AU - Costa-Silva,Matheus F, AU - de Oliveira,Jaquelline G, AU - Farias,Roberto H, AU - Noronha,Tatiana G, AU - Lemos,Jandira A, AU - von Doellinger,Vanessa dos R, AU - Simões,Marisol, AU - de Souza,Mirian M, AU - Malaquias,Luiz C, AU - Persi,Harold R, AU - Pereira,Jorge M, AU - Martins,José A, AU - Dornelas-Ribeiro,Marcos, AU - Vinhas,Aline de A, AU - Alves,Tatiane R, AU - Maia,Maria de L, AU - Freire,Marcos da S, AU - Martins,Reinaldo de M, AU - Homma,Akira, AU - Romano,Alessandro P M, AU - Domingues,Carla M, AU - Tauil,Pedro L, AU - Vasconcelos,Pedro F, AU - Rios,Maria, AU - Caldas,Iramaya R, AU - Camacho,Luiz A, AU - Martins-Filho,Olindo Assis, PY - 2015/9/12/entrez PY - 2015/9/12/pubmed PY - 2016/12/15/medline KW - cytokine KW - duration of immunity KW - flow cytometry KW - memory cells and vaccination KW - vaccine KW - yellow fever SP - 491 EP - 502 JF - Human vaccines & immunotherapeutics JO - Hum Vaccin Immunother VL - 12 IS - 2 N2 - A single vaccination of Yellow Fever vaccines is believed to confer life-long protection. In this study, results of vaccinees who received a single dose of 17DD-YF immunization followed over 10 y challenge this premise. YF-neutralizing antibodies, subsets of memory T and B cells as well as cytokine-producing lymphocytes were evaluated in groups of adults before (NVday0) and after (PVday30-45, PVyear1-4, PVyear5-9, PVyear10-11, PVyear12-13) 17DD-YF primary vaccination. YF-neutralizing antibodies decrease significantly from PVyear1-4 to PVyear12-13 as compared to PVday30-45, and the seropositivity rates (PRNT≥2.9Log10mIU/mL) become critical (lower than 90%) beyond PVyear5-9. YF-specific memory phenotypes (effector T-cells and classical B-cells) significantly increase at PVday30-45 as compared to naïve baseline. Moreover, these phenotypes tend to decrease at PVyear10-11 as compared to PVday30-45. Decreasing levels of TNF-α(+) and IFN-γ(+) produced by CD4(+) and CD8(+) T-cells along with increasing levels of IL-10(+)CD4(+)T-cells were characteristic of anti-YF response over time. Systems biology profiling represented by hierarchic networks revealed that while the naïve baseline is characterized by independent micro-nets, primary vaccinees displayed an imbricate network with essential role of central and effector CD8(+) memory T-cell responses. Any putative limitations of this cross-sectional study will certainly be answered by the ongoing longitudinal population-based investigation. Overall, our data support the current Brazilian national immunization policy guidelines that recommend one booster dose 10 y after primary 17DD-YF vaccination. SN - 2164-554X UR - https://www.unboundmedicine.com/medline/citation/26360663/Booster_dose_after_10_years_is_recommended_following_17DD_YF_primary_vaccination_ L2 - https://www.tandfonline.com/doi/full/10.1080/21645515.2015.1082693 DB - PRIME DP - Unbound Medicine ER -